While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.
The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.
ACP 2025: GLP-1 medications are advancing obesity care, but lifestyle changes and bariatric surgery remain key components. Laura Davisson, MD, discusses how to personalize treatment strategies.
Following a Mediterranean-style diet and a prescribed regimen of physical activity was significantly protective of BMD, particularly at the lumbar level, over 3 years.
The FDA and Novo Nordisk are urging health care professionals to check semaglutide (Ozempic) injection 1 mg lot PAR0362 with serials starting 51746517.
ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.
Loss of lean muscle mass along with fat mass is a concerning side effect of the incretin-based antiobesity medications, making the new study results encouraging.
ACP 2025: Laura Davisson, MD, outlines how PCPs can navigate GLP-1 medication coverage issues and why to consider recent cash-pay options.
Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.
Your daily dose of the clinical news you may have missed.